ATXS
Price
$3.92
Change
-$0.00 (-0.00%)
Updated
May 22 closing price
Capitalization
230.25M
80 days until earnings call
SVRA
Price
$2.93
Change
+$0.02 (+0.69%)
Updated
May 22 closing price
Capitalization
506.41M
76 days until earnings call
Interact to see
Advertisement

ATXS vs SVRA

Header iconATXS vs SVRA Comparison
Open Charts ATXS vs SVRABanner chart's image
Astria Therapeutics
Price$3.92
Change-$0.00 (-0.00%)
Volume$465.55K
Capitalization230.25M
Savara
Price$2.93
Change+$0.02 (+0.69%)
Volume$1.04M
Capitalization506.41M
ATXS vs SVRA Comparison Chart
Loading...
ATXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SVRA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ATXS vs. SVRA commentary
May 23, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ATXS is a Hold and SVRA is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
May 23, 2025
Stock price -- (ATXS: $3.92 vs. SVRA: $2.93)
Brand notoriety: ATXS and SVRA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ATXS: 96% vs. SVRA: 102%
Market capitalization -- ATXS: $230.25M vs. SVRA: $506.41M
ATXS [@Biotechnology] is valued at $230.25M. SVRA’s [@Biotechnology] market capitalization is $506.41M. The market cap for tickers in the [@Biotechnology] industry ranges from $307B to $0. The average market capitalization across the [@Biotechnology] industry is $2.24B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ATXS’s FA Score shows that 0 FA rating(s) are green whileSVRA’s FA Score has 0 green FA rating(s).

  • ATXS’s FA Score: 0 green, 5 red.
  • SVRA’s FA Score: 0 green, 5 red.
According to our system of comparison, both ATXS and SVRA are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ATXS’s TA Score shows that 4 TA indicator(s) are bullish while SVRA’s TA Score has 4 bullish TA indicator(s).

  • ATXS’s TA Score: 4 bullish, 4 bearish.
  • SVRA’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, ATXS is a better buy in the short-term than SVRA.

Price Growth

ATXS (@Biotechnology) experienced а -1.75% price change this week, while SVRA (@Biotechnology) price change was -5.79% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.72%. For the same industry, the average monthly price growth was +2.76%, and the average quarterly price growth was -2.87%.

Reported Earning Dates

ATXS is expected to report earnings on Aug 11, 2025.

SVRA is expected to report earnings on Aug 07, 2025.

Industries' Descriptions

@Biotechnology (+0.72% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SVRA($506M) has a higher market cap than ATXS($230M). SVRA YTD gains are higher at: -4.560 vs. ATXS (-56.152). SVRA has higher annual earnings (EBITDA): -88.58M vs. ATXS (-111.56M). ATXS has more cash in the bank: 328M vs. SVRA (219M). ATXS has less debt than SVRA: ATXS (5.35M) vs SVRA (26.7M). ATXS (0) and SVRA (0) have equivalent revenues.
ATXSSVRAATXS / SVRA
Capitalization230M506M45%
EBITDA-111.56M-88.58M126%
Gain YTD-56.152-4.5601,231%
P/E RatioN/AN/A-
Revenue00-
Total Cash328M219M150%
Total Debt5.35M26.7M20%
FUNDAMENTALS RATINGS
ATXS vs SVRA: Fundamental Ratings
ATXS
SVRA
OUTLOOK RATING
1..100
2317
VALUATION
overvalued / fair valued / undervalued
1..100
58
Fair valued
72
Overvalued
PROFIT vs RISK RATING
1..100
10083
SMR RATING
1..100
9494
PRICE GROWTH RATING
1..100
9160
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ATXS's Valuation (58) in the Biotechnology industry is in the same range as SVRA (72). This means that ATXS’s stock grew similarly to SVRA’s over the last 12 months.

SVRA's Profit vs Risk Rating (83) in the Biotechnology industry is in the same range as ATXS (100). This means that SVRA’s stock grew similarly to ATXS’s over the last 12 months.

SVRA's SMR Rating (94) in the Biotechnology industry is in the same range as ATXS (94). This means that SVRA’s stock grew similarly to ATXS’s over the last 12 months.

SVRA's Price Growth Rating (60) in the Biotechnology industry is in the same range as ATXS (91). This means that SVRA’s stock grew similarly to ATXS’s over the last 12 months.

SVRA's P/E Growth Rating (100) in the Biotechnology industry is in the same range as ATXS (100). This means that SVRA’s stock grew similarly to ATXS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ATXSSVRA
RSI
ODDS (%)
Bullish Trend 3 days ago
81%
Bearish Trend 1 day ago
83%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
77%
Bullish Trend 1 day ago
83%
Momentum
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend 1 day ago
82%
MACD
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend 1 day ago
80%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
81%
Bearish Trend 1 day ago
85%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend 1 day ago
85%
Advances
ODDS (%)
Bullish Trend 4 days ago
80%
Bullish Trend 4 days ago
80%
Declines
ODDS (%)
Bearish Trend 15 days ago
90%
Bearish Trend 18 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
87%
Bullish Trend 1 day ago
81%
Aroon
ODDS (%)
Bullish Trend 1 day ago
87%
Bullish Trend 1 day ago
86%
View a ticker or compare two or three
Interact to see
Advertisement
ATXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SVRA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
SHEAX8.570.06
+0.71%
American Beacon Shapiro SMID Cap Eq A
MSRRX54.42N/A
N/A
MFS Research R2
FEICX33.35N/A
N/A
Fidelity Advisor Equity Income C
AGORX10.01N/A
N/A
American Century Focused Global Gr R
GVIZX11.81N/A
N/A
GuideStone Funds Value Equity Index Inv

ATXS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ATXS has been loosely correlated with XENE. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if ATXS jumps, then XENE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ATXS
1D Price
Change %
ATXS100%
N/A
XENE - ATXS
55%
Loosely correlated
+0.10%
CRNX - ATXS
54%
Loosely correlated
+0.53%
KYMR - ATXS
54%
Loosely correlated
N/A
TRDA - ATXS
53%
Loosely correlated
-0.91%
APGE - ATXS
52%
Loosely correlated
+0.45%
More

SVRA and

Correlation & Price change

A.I.dvisor indicates that over the last year, SVRA has been loosely correlated with LRMR. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if SVRA jumps, then LRMR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SVRA
1D Price
Change %
SVRA100%
+0.69%
LRMR - SVRA
48%
Loosely correlated
N/A
KYMR - SVRA
45%
Loosely correlated
N/A
CRNX - SVRA
43%
Loosely correlated
+0.53%
ATXS - SVRA
43%
Loosely correlated
N/A
CCCC - SVRA
42%
Loosely correlated
N/A
More